| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 38.4 | 13.3 |
| Net income | -48.1 | -48.2 |
| EPS (diluted, $ a share) | $-7.36 | $-16.92 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +189.1% |
|---|---|
| Operating margin | 18.7% |
10-Q filed with the SEC, NASDAQ: GOSS. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Gossamer Bio, Inc.: key numbers
- Share price
- $10.98Close, Nov 16
- Market cap
- $67.2M
- Shares outstanding
- 6.12MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Gossamer Bio, Inc.
All →Gossamer Bio Financial Results
Gossamer Bio reported Q3 2026 financial results, highlighting the submission of its first New Drug Application (NDA) to the FDA for seralutinib in PAH. The company also noted a structured private placement that provided $25 million upfront and could unlock an additional $125 million upon FDA acceptance of the NDA. Additionally, the company completed a 1-for-80 reverse stock split in September 2026 to regain Nasdaq compliance.
- Term
- Q3 2026
“Submitting our first NDA marks an important milestone for Gossamer in our continued efforts to bring seralutinib to patients living with PAH. Furthermore, FDA acceptance of the application in 2026 would, subject to other customary closing conditions, unlock up to approximately $125 million in additional committed capital to support our priorities, including preparations for a potential launch. We remain focused on supporting the FDA’s review and preparing for a potential commercial launch of seralutinib in 2027.”
Faheem Hasnain, Chairman, Co-Founder and Chief Executive Officer
Gossamer Bio Capital Raise
Gossamer Bio stockholders approved the potential issuance of common stock exceeding 20% of outstanding shares in connection with a Securities Purchase Agreement dated August 20, 2026. The approval covers shares issuable upon the exercise of Pre-Funded Warrants, FDA Approval Warrants, and the conversion of Series A-1, A-2, and A-3 Preferred Stock, satisfying Nasdaq Listing Rules 5635(c) and 5635(d).
Gossamer Bio Nasdaq/NYSE Compliance Notice
Gossamer Bio has regained compliance with Nasdaq's minimum bid price requirement of $1.00 per share, resolving a deficiency notice originally received on April 8, 2026. The company achieved compliance following a 1-for-80 reverse stock split that became effective on September 10, 2026, and the matter is now closed.
- Counterparty
- The Nasdaq Stock Market LLC
Gossamer Bio Other 8-K Filing
Gossamer Bio has submitted its first New Drug Application (NDA) to the FDA for seralutinib for the treatment of pulmonary arterial hypertension (PAH). The submission is supported by data from the Phase 3 PROSERA and Phase 2 TORREY studies, following a Pre-NDA meeting with the regulator in June 2026. The FDA is expected to determine whether to accept the application for filing later this year.
- Counterparty
- FDA
Gossamer Bio Executive Compensation
Gossamer Bio appointed Gregory A. Ciongoli to its Board of Directors and Audit Committee, effective September 16, 2026. Mr. Ciongoli will receive an annual cash retainer of $40,000 for board service and $7,500 for committee service, along with future equity awards under the non-employee director compensation program. He was previously a purchaser in the company's 2026 private placement (PIPE) transaction.
- Counterparty
- Gregory A. Ciongoli